Dechra Pharmaceuticals (BATS-CHIXE:DPHL) - Stock Price, News & Analysis

DPHL Stock Overview

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. More details

DPHL fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	4/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Rewards

Earnings are forecast to grow 62.48% per year

Risk Analysis

Interest payments are not well covered by earnings

Dechra Pharmaceuticals PLC Competitors

Hikma Pharmaceuticals

LSE:HIK

UK£4.3b

HUTCHMED (China)

AIM:HCM

UK£2.4b

Indivior

LSE:INDV

UK£1.1b

GSK

LSE:GSK

UK£54.8b

Price History & Performance

Summary of all time highs, changes and price drops for Dechra Pharmaceuticals
Historical stock prices
Current Share Price	UK£38.70
52 Week High	UK£38.84
52 Week Low	UK£24.74
Beta	0.78
11 Month Change	0.55%
3 Month Change	2.27%
1 Year Change	35.79%
33 Year Change	5.91%
5 Year Change	63.71%
Change since IPO	744.98%

Recent updates

Shareholder Returns

	DPHL	GB Pharmaceuticals	GB Market
7D	0.2%	4.5%	2.2%
1Y	35.8%	0.7%	8.0%

Return vs Industry: DPHL exceeded the UK Pharmaceuticals industry which returned -2.4% over the past year.

Return vs Market: DPHL exceeded the UK Market which returned -6.7% over the past year.

Price Volatility

Is DPHL's price volatile compared to industry and market?
DPHL volatility
DPHL Average Weekly Movement	0.5%
Pharmaceuticals Industry Average Movement	6.6%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: DPHL has not had significant price volatility in the past 3 months.

Volatility Over Time: DPHL's weekly volatility has decreased from 6% to 1% over the past year.

About the Company

Founded	Employees	CEO	Website
1997	2,457	Ian Page	www.dechra.com

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, internal medicine, and nutrition products supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases.

Dechra Pharmaceuticals PLC Fundamentals Summary

How do Dechra Pharmaceuticals's earnings and revenue compare to its market cap?
DPHL fundamental statistics
Market cap	UK£4.40b
Earnings (TTM)	-UK£27.90m
Revenue (TTM)	UK£761.50m

5.8x

P/S Ratio

-157.8x

P/E Ratio

Is DPHL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DPHL income statement (TTM)
Revenue	UK£761.50m
Cost of Revenue	UK£331.90m
Gross Profit	UK£429.60m
Other Expenses	UK£457.50m
Earnings	-UK£27.90m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.24
Gross Margin	56.42%
Net Profit Margin	-3.66%
Debt/Equity Ratio	64.6%

How did DPHL perform over the long term?

See historical performance and comparison

DPHL Stock Overview

Rewards

Risk Analysis

Dechra Pharmaceuticals PLC Competitors

LSE:HIK

UK£4.3b

AIM:HCM

UK£2.4b

LSE:INDV

UK£1.1b

LSE:GSK

UK£54.8b

Price History & Performance

Recent News & Updates

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Recent updates

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals Intends to Delist from Official List

First half 2023 earnings released: EPS: UK£0.20 (vs UK£0.38 in 1H 2022)

Investor sentiment improved over the past week

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index

Now 21% undervalued after recent price drop

Less than half of directors are independent

Upcoming dividend of UK£0.33 per share

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 19, 2023

Full year 2022 earnings released: EPS: UK£0.54 (vs UK£0.51 in FY 2021)

Dechra Pharmaceuticals plc Proposes Final Dividend for the Year Ended June 30, 2022

Dechra Pharmaceuticals PLC (LSE:DPH) acquired Med-Pharmex, Inc. from DW Management Services, LLC for $260 million on a debt-free and cash-free basis.

Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million.

Now 21% undervalued after recent price drop

Dechra Pharmaceuticals PLC Announces Executive Changes

Less than half of directors are independent

Non-Executive Chairman recently bought UK£99k worth of stock

Upcoming dividend of UK£0.12 per share

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Dechra Pharmaceuticals PLC Declares Interim Dividend, Payable on April 7, 2022

Dechra Pharmaceuticals plc Announces Executive Changes

Dechra Pharmaceuticals PLC (LSE:DPH) agreed to acquire Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc.

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Non-Executive Director Denise Goode has left the company

Upcoming dividend of UK£0.29 per share

Board Member recently sold UK£875k worth of stock

Full year 2021 earnings released: EPS UK£0.51 (vs UK£0.33 in FY 2020)

Board Member recently sold UK£963k worth of stock

First half 2021 earnings released: EPS UK£0.22 (vs UK£0.13 in 1H 2020)

Akston Biosciences Signs Licensing Agreement with Dechra Pharma for Aks-425C

New 90-day high: UK£37.50

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 21, 2021

New 90-day high: UK£35.98

Dechra Pharmaceuticals PLC Launches Mirataz

Dechra Pharmaceuticals PLC to Report First Half, 2021 Results on Feb 22, 2021

Shareholder Returns

Price Volatility

About the Company

Dechra Pharmaceuticals PLC Fundamentals Summary

5.8x

-157.8x

Earnings & Revenue